FT Markets Data
Piramal Pharma Ltd

Piramal Pharma Limited Announces Results for Q4 and FY2025

MUMBAI, India , May 14, 2025 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full Year (FY) ended 31stMarch 2025.

Piramal Pharma Ltd Logo

 

 

Consolidated Financial Highlights

(in ₹ Crores or as stated)

Particulars

Q4FY25

Q4FY24

YoY Growth

FY25

FY24

YoY Growth

Revenue from Operations

2,754

2,552

8 %

9,151

8,171

12 %

   CDMO

1,788

1,649

8 %

5,447

4,750

15 %

   CHG

705

667

6 %

2,633

2,449

8 %

   ICH

274

238

15 %

1,093

985

11 %

EBITDA

603

556

8 %

1,580

1,372

15 %

EBITDA Margin

22 %

22 %


17 %

17 %


PAT (before exceptional item)

154

132

16 %

91

81

13 %

Exceptional Item*

-

(31)

NM

-

(63)

NM

PAT (after exceptional item)

154

101

52 %

91

18

411 %

* Q4FY24 - ₹ 31 Cr towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized;
Q3FY24 - ₹ 32 Cr. related to non-recurring charges towards product recall triggered by a 3rd party supplier

 

Key Highlights for Q4FY25/FY25

  • Revenue from Operations grew by 8% YoY and 12% YoY in Q4FY25 and FY25 respectively, driven primarily by CDMO business especially from on-patent commercial manufacturing
  • EBITDA grew by 8% YoY and 15% YoY in Q4FY25 and FY25 respectively, on account of operating leverage, cost optimization, and operational excellence initiatives
  • Net-Debt to EBITDA ratio improved to 2.7x Vs. 5.6x in FY23
  • Best-in-Class Quality Track Record – Continue to maintain our 'Zero OAIs' status since 2011
  • Sustainability Efforts Yielding Results – Significant enhancement in S&P Global and EcoVadis ESG scores  

Nandini Piramal, Chairperson, Piramal Pharma Limited said, "FY25 has been a steady year for the company as we crossed $1Bn in revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth. During the year, we progressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business.

We believe, we are on track to deliver on our FY2030 aspirations of becoming a $2bn revenue company with 25% EBITDA margins and high teens ROCE ."

 

Key Business Highlights for Q4 and FY2025

Contract Development and Manufacturing Organization (CDMO) :

-  Increasing contribution from Innovation1 related work - Up from 50% in FY24 to 54% in FY25, driven by commercial manufacturing of on-patent molecules

-  Robust growth in on-patent commercial manufacturing revenues - Grew by over 50% YoY to reach $179mn (Vs. $116mn in FY24 and $53mn in FY23)

-  Revenues from differentiated offerings grew 28% YoY, contributing to 49% of CDMO revenues

-  Healthy growth in API generics business

-  YoY improvement in EBITDA margin driven by better procurement strategies, cost optimization and operational excellence initiatives

-  Maintained our best-in-class quality track record - Successfully cleared 36 regulatory inspections and 165 customer audits in FY25 without any major observations

 

Complex Hospital Generics (CHG):

-  Inhalation Anesthesia (IA) - Major GPO contract renewal and order wins supporting IA sales in the US. Witnessing encouraging traction in the RoW markets

-  Capacity expansion in India completed and commercialized on time; poised to capitalize on ~US$400 mn2 Sevoflurane market opportunity in the RoW markets

-  Maintained our #1 Rank in the US in Sevoflurane (44% market share2) and in intrathecal Baclofen (75% market share2)

-   Received approval for Neoatricon®3 for multiple markets in EU and UK by our partner BrePco Pharma. Neoatricon® is the only pre-diluted, age-appropriate formulation of dopamine, approved for treating children and infants

-  Moderation in EBITDA margins due to some non-recurring expenses and capacity expansion in India. However, recovery expected from FY26 with commercialization of these added capacities

 

India Consumer Healthcare (ICH):

-  ICH business crossed the strategic revenue milestone of ₹ 1,000 croresduring the year

-  Power Brands continue to grow strength to strength with 20% YoY during FY25. Power Brands contributed to 49% of total ICH sales

o  Excluding i-range, which was impacted by regulatory price control, growth in power brands was about 26% in FY25

-  New Product Launches - Added 21 new products and 31 new SKUs in FY25

-  Investments in Media and Promotions – 11% of ICH sales in FY25. Launched our new media campaign with Yami Gautam for Little's

-  E-commerce sales grew at 39% YoY in FY25, contributing 21% to ICH sales,. Present on more than 20 e-commerce platforms

1. Discovery + Development + Commercial Manufacturing of products under patent; 2. As per IQVIA data, September 2024; 3. Neoatricon® is developed by BrePco Biopharma;
we have secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing in these regions. 

 

 

Consolidated Profit and Loss Statement

(in ₹ Crores or as stated)

Particulars

Quarterly

Full Year

Q4FY25

Q4FY24

YoY  Change

FY25

FY24

YoY  Change

Revenue from Operations

2,754

2,552

8 %

9,151

8,171

12 %

Other Income

42

26

59 %

135

175

(23 %)

Total Income

2,796

2,579

8 %

9,286

8,347

11 %

Material Cost

955

1,014

(6 %)

3,232

2,954

9 %

Employee Expenses

612

494

24 %

2,307

2,030

14 %

Other Expenses

626

514

22 %

2,167

1,991

9 %

EBITDA

603

556

8 %

1,580

1,372

15 %

Finance Cost

104

114

(9 %)

422

448

(6 %)

Depreciation

243

196

24 %

816

741

10 %

Share of net profit of associates

16

12

35 %

73

59

23 %

Profit Before Tax

273

258

6 %

415

242

71 %

Tax

119

126

(5 %)

324

161

100 %

Net Profit after Tax (before exceptional item)

154

132

16 %

91

81

13 %

Exceptional item*

-

(31)

NM

-

(63)

NM

Net Profit after Tax (after exceptional item)

154

101

52 %

91

18

411 %

* Q4FY24 - ₹ 31 Cr towards non-cash write down of investment and license rights in relation to a certain third-party product no longer being commercialized;
Q3FY24 - ₹ 32 Cr. related to non-recurring charges towards product recall triggered by a 3rd party supplier

 

 

Consolidated Balance Sheet

 (In ₹ Crores)

   Key Balance Sheet Items

As at

31-Mar-25

31-Mar-24

Total Equity

8,125

7,911

Net Debt

4,199

3,932

Total

12,324

11,843




Net Fixed Assets

9,110

9,106

    Tangible Assets

4,534

4,250

    Intangible Assets including goodwill

3,599

3,740

    CWIP (including IAUD*)

977

1,116

Net Working Capital

2,798

2,339

Other Assets#

416

398

Total Assets

12,324

11,843

*IAUD – Intangible Assets Under Development

# Other Assets include Investments and Deferred Tax Assets (Net)

 

 

 

Q4FY25/FY25 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on 15thMay 2025 from 9:30 AM to 10:15 AM(IST)to discuss its Q4 and FY25 Results.

The dial-in details for the call are as under:

Event

Location & Time

Telephone Number

Conference call on
15th May, 2025

India – 09:30 AM IST

+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)

1 800 120 1221 (Toll free number)

USA – 12:00 AM

(Eastern Time – New York)

Toll free number

18667462133

UK – 05:00 AM

(London Time)

Toll free number

08081011573

Singapore – 12:00 PM

(Singapore Time)

Toll free number

8001012045

Hong Kong – 12:00 PM

(Hong Kong Time)

Toll free number

800964448

Express Join with Diamond Pass™

Please use this link for prior registration to reduce wait time at the time of joining the call –https://clicktime.symantec.com/15tTDy8HiefVsfhet88NZ?h=fW3GbZrqogMd-yABQyRMy2isMM11wQD-TSFMQrYI2gs=&u=https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber%3D6099661%26linkSecurityString%3D26cd0b7825Click Here

 

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

* Includes one facility via PPL's minority investment in Yapan Bio.

For more information, visit: Piramal Pharma | LinkedIn

Logo - https://mma.prnewswire.com/media/1855206/4913155/Piramal_Pharma_Limited_Logo.jpg

 

 

                      

Cision View original content:https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-results-for-q4-and-fy2025-302455711.html

SOURCE Piramal Pharma Ltd